4 ms·
> A team in Hong Kong has announced that in their cell assays the Omicron variant seems to reproduce up to 70 times faster in the upper respiratory tract, while
by mdp2021 5y ago
> A team in Hong Kong has announced that in their cell assays the Omicron variant seems to reproduce up to 70 times faster in the upper respiratory tract, while at the same time being much slower to reproduce in lung tissue
> What About Immune Evasion? How Much Protection Do Vaccines Provide? This part of the story isn't completely worked out yet... Most of that [information] is antibody-based data, and ... while this is important, it is not the last word on real-world immune protection[: ]T-cell mechanisms are also crucial, and T-cell data are much harder to come by
> the Pfizer protease inhibitor ... does appear to be just as effective against Omicron, but its supply will not be enough to make any real difference at all in the coming weeks
From the "introduction" of Dec 2:
> Where Did It Come From? Omicron ... is not a direct descendant of the Delta strains ... An immediate hypothesis was that Omicron may have developed in a single immunocompromised human patient over a period of weeks or months[: ... y]ou don't just immediately kill everything off - you give the virus or bacterium a chance to overcome a lesser challenge before turning up the pressure a bit more, letting mutations accumulate and try their worth over and over as the challenge slowly increases. That's just what's going on inside a coronavirus patient if they can't mount a full immune response. The virus and the immune system engage in a prolonged battle where neither one can land a decisive blow, and things just keep on evolving. This is why they tell you to take your full course of antibiotics when you have a bacterial infection, and why effective vaccines actually suppress variant formation: if you kill off the pathogens as quickly as possible, they don't have time to explore their mutational landscape
- loeg 5y ago> the Pfizer protease inhibitor ... supply will not be enough to make any real difference at all in the coming weeks Tautalogically so in the US, anyway, where the FDA has inexplicably still has not approved (or emergency authorized) it for use.
- rossdavidh 5y agoOn one level I agree, but realistically I think they may not feel much of a hurry to do so since there isn't a significant supply ready to distribute. My understanding is that they already have authorization to use whatever they have, essentially as additional testing.
- loeg 5y agoAs of Nov 29, > Pfizer now expects to make 80 million courses of COVID drug Paxlovid by the end of 2022 That's a ton of supply!
- wiml 5y agoI'm not sure what you're quoting from, but ... that's more than a year from now.
- bsder 5y agoEnd of 2022. That doesn't help us in 2021.
- senectus1 5y agoto me its sounds like its too slow. how many variant have we had this year already? I hope the pill from pfizer can withstand the evolution cycle of this blasted virus.
- tempnow987 5y agoFor those following - these treatments are 40 pill treatments. For the 50M odd cases we've had we'd need 40*50M pills (2 billion pills). Assume a daily global rate of around 600K cases per day we'd need 24M pills per day. USA alone is perhaps 100K cases, so 4M pills per day. Do they really have this volume ready to go? -- I'm not aware of a single study showing that for vaccinated folks the pills do anything. Not saying they don't, but it would be helpful to have ONE study. -- As to why the FDA has not approved, they are reasonably clear. One issue is that COVID, and particularly omicron variant which dominates, is just not that lethal. EDIT: This part is incorrect below These pills work in interesting ways, ie, generating MORE mutations. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells https://pubmed.ncbi.nlm.nih.gov/33961695/ https://pubmed.ncbi.nlm.nih.gov/33961695/ So before you jam 2 billion doses into folks there is going to be a bit of an evaluation. If Omicron turns out to have high fatality rates then I suspect things like these therapies will be fast tracked a bit more.
- tguvot 5y agoyou describing here merck treatment, not pfizers
- loeg 5y ago> For those following - these treatments are 40 pill treatments. > These pills work in interesting ways, ie, generating MORE mutations. > β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells https://pubmed.ncbi.nlm.nih.gov/33961695/ https://pubmed.ncbi.nlm.nih.gov/33961695/ You're way off-base. You're talking about Merck's Molnupiravir (Lagevrio), which is both less effective (~30% vs ~88%) and already approved. Pfizer's Paxlovid (Nirmatrelvir) is not mutagenic. It is a 15 pill course (5 days x 3 per day), not 40. Also, Pfizer thinks as of Nov 29 that they can make 80M courses by EOY. The US has purchased at least 10M of them.
- mcguire 5y agoHas Pfizer submitted the clinical trial data to the FDA? The last I heard (a week ago?) was that they were going to do it "in a few days".
- loeg 5y agoThis presser from the 14th claims final data was submitted[1]. I don’t know the exact details of both processes, but somehow the EU has authorized it already, on presumably the same data. [1]: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results https://www.pfizer.com/news/press-release/press-release-deta...